Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts


  HIV Infection

  Free Subscription


Articles published in Lancet Infect Dis

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    April 2025
  1. LAYTON GR, Veater JB, Thombre R, Afshar B, et al
    Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis.
    Lancet Infect Dis. 2025;25:e253-e254.
    PubMed    


    March 2025
  2. SASO A, Kanteh E, Jeffries D, Okoye M, et al
    The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.
    Lancet Infect Dis. 2025 Mar 25:S1473-3099(25)00072.
    PubMed     Abstract available


  3. MCCLURE M, Gandhi M
    Threat of HIV and tuberculosis drug resistance after US funding cuts.
    Lancet Infect Dis. 2025 Mar 20:S1473-3099(25)00209.
    PubMed    


  4. HILLUS D, Le NH, Tober-Lau P, Fietz AK, et al
    Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study.
    Lancet Infect Dis. 2025 Mar 18:S1473-3099(25)00018.
    PubMed     Abstract available


  5. BORGES AH, Russell M, Tait D, Scriba TJ, et al
    Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlle
    Lancet Infect Dis. 2025 Mar 5:S1473-3099(24)00814.
    PubMed     Abstract available


    February 2025
  6. PROAL AD, Aleman S, Bomsel M, Brodin P, et al
    Targeting the SARS-CoV-2 reservoir in long COVID.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(24)00769.
    PubMed     Abstract available


    January 2025
  7. DUNSMUIR H
    HIV and rights for queer communities in Ghana.
    Lancet Infect Dis. 2025 Jan 27:S1473-3099(25)00066.
    PubMed    


    December 2024
  8. PAINTER C, Limmathurotsakul D, Roberts T, van Doorn HR, et al
    Sustainable antimicrobial resistance surveillance: time for a global funding mechanism.
    Lancet Infect Dis. 2024 Dec 17:S1473-3099(24)00649.
    PubMed     Abstract available


  9. KIRBY T
    Justyna Kowalska-reaching underserved people with HIV.
    Lancet Infect Dis. 2024;24:1303.
    PubMed    


    November 2024
  10. BAGCCHI S
    Spreading awareness about HIV transmission.
    Lancet Infect Dis. 2024 Nov 28:S1473-3099(24)00803.
    PubMed    


  11. NAIDOO K, Perumal R
    First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis.
    Lancet Infect Dis. 2024 Nov 26:S1473-3099(24)00653.
    PubMed    


  12. HOLT E
    Gilead under fire over HIV drug licensing.
    Lancet Infect Dis. 2024 Nov 8:S1473-3099(24)00747.
    PubMed    


    October 2024
  13. DAS NEVES MARTINS FE, Chiang JO, Nunes BTD, Ribeiro BFR, et al
    Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series.
    Lancet Infect Dis. 2024 Oct 15:S1473-3099(24)00617.
    PubMed     Abstract available


  14. BAGCCHI S
    HIV stigma in health-care settings in Europe and central Asia.
    Lancet Infect Dis. 2024;24:e622.
    PubMed    


  15. ORKIN C, Ring K
    Implementing long-acting injectable cabotegravir and rilpivirine in Africa.
    Lancet Infect Dis. 2024;24:1060-1061.
    PubMed    


    September 2024
  16. WASSERMAN S, Donovan J, Kestelyn E, Watson JA, et al
    Advancing the chemotherapy of tuberculous meningitis: a consensus view.
    Lancet Infect Dis. 2024 Sep 26:S1473-3099(24)00512.
    PubMed     Abstract available


  17. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    PubMed     Abstract available


  18. PROCHAZKA M, Vinti P, Hoxha A, Seale A, et al
    Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey.
    Lancet Infect Dis. 2024 Sep 18:S1473-3099(24)00531.
    PubMed     Abstract available


  19. BAPOLISI WA, Krasemann S, Wayengera M, Kirenga B, et al
    Mpox outbreak-tecovirimat resistance, management approaches, and challenges in HIV-endemic regions.
    Lancet Infect Dis. 2024 Sep 10:S1473-3099(24)00591.
    PubMed    


  20. HOLT E
    Setbacks and advances in the global HIV response.
    Lancet Infect Dis. 2024;24:e554.
    PubMed    


  21. PANNIKOTTU J, Reuter A, Pietersen E, Makhanda G, et al
    Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis.
    Lancet Infect Dis. 2024;24:947-949.
    PubMed    


    August 2024
  22. STARBUCK E
    Biopolitical precarity for women with HIV in South Africa.
    Lancet Infect Dis. 2024 Aug 26:S1473-3099(24)00572.
    PubMed    


  23. VANBAELEN T, Manoharan-Basil SS, Kenyon C
    Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance.
    Lancet Infect Dis. 2024 Aug 21:S1473-3099(24)00502.
    PubMed    


  24. RACCAGNI AR, Castagna A, Nozza S
    Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues.
    Lancet Infect Dis. 2024 Aug 13:S1473-3099(24)00528.
    PubMed    


    July 2024
  25. GRAY GE, Mngadi K, Lavreys L, Nijs S, et al
    Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00358.
    PubMed     Abstract available


  26. LEHMANN C, Schommers P
    The need for novel approaches to HIV-1 vaccine development.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00398.
    PubMed    


    June 2024
  27. DECROO T, Mesic A, Decuyper I
    Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00294.
    PubMed    


  28. KOROTYCH O, Achar J, Gurbanova E, Hovhannesyan A, et al
    Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00228.
    PubMed     Abstract available


  29. JOSEPH DAVEY D, de Voux A, Hlatshwayo L, Nelson A, et al
    Prevention of congenital syphilis within antenatal PrEP services in South Africa: missed opportunities.
    Lancet Infect Dis. 2024;24:571-572.
    PubMed    


    May 2024
  30. KITYO C, Mambule IK, Musaazi J, Sokhela S, et al
    Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289.
    PubMed     Abstract available


  31. MOLINA JM, Bercot B, Assoumou L, Rubenstein E, et al
    Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design.
    Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236.
    PubMed     Abstract available


  32. CEVIK M, Thompson LC, Upton C, Rolla VC, et al
    Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Lancet Infect Dis. 2024 May 17:S1473-3099(24)00223.
    PubMed     Abstract available


    April 2024
  33. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    PubMed     Abstract available



  34. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    PubMed     Abstract available


  35. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    PubMed    


    March 2024
  36. CHAKAYA J, Fatma R, Cader M, Harries AD, et al
    Post-tuberculosis lung disease: is there a light at the end of tunnel?
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00136.
    PubMed    


  37. NAIDOO K, Perumal R, Cox H, Mathema B, et al
    The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience.
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00144.
    PubMed     Abstract available


  38. LADHANI SN, White PJ, Campbell H, Mandal S, et al
    Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Lancet Infect Dis. 2024 Mar 20:S1473-3099(24)00031.
    PubMed     Abstract available



  39. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    PubMed     Abstract available


  40. STUCK L, Klinkenberg E, Abdelgadir Ali N, Basheir Abukaraig EA, et al
    Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis.
    Lancet Infect Dis. 2024 Mar 12:S1473-3099(24)00011.
    PubMed     Abstract available


  41. COHN J, Mendelson M, Kanj SS, Shafiq N, et al
    Accelerating antibiotic access and stewardship: a new model to safeguard public health.
    Lancet Infect Dis. 2024 Mar 11:S1473-3099(24)00070.
    PubMed     Abstract available


  42. DAS M
    UNICEF report reveals gender gaps persist in HIV.
    Lancet Infect Dis. 2024;24:e159.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.